Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Royalty Pharma PLC maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 62.44%, while the net margin is 57.22%. These profitability ratios, combined with a Return on Equity (ROE) of 11.49%, provide a clear picture of how effectively RPRX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, RPRX competes directly with industry leaders such as BIIB and INSM. With a market capitalization of $27.38B, it holds a significant position in the sector. When comparing efficiency, RPRX's gross margin of 100.00% stands against BIIB's 72.46% and INSM's 82.51%. Such benchmarking helps identify whether Royalty Pharma PLC is trading at a premium or discount relative to its financial performance.
